Loading...
OTCM
XENO
Market cap4kUSD
Sep 14, Last price  
0.00USD
Name

Xeno Transplants Corp

Chart & performance

D1W1MN
OTCM:XENO chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0
Net income
-128k
L+174.74%
-32,717-46,657-128,185
CFO
-129k
L+388.14%
-39,267-26,433-129,031

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Xeno Transplants Corporation functions as a biotechnology firm dedicated to research and development. Leveraging a specific licensing agreement with Massachusetts General Hospital, the company aims to innovate, produce, commercialize, and implement products and methodologies for public application in the field of xenotransplantation. The primary objective of this xenotransplantation research is to alleviate the critical scarcity of human cells, tissues, and organs required for medical transplants. This is achieved by pioneering techniques that enable the transfer of biological components—such as cells, tissues, and organs—from non-human species, including pigs, into human recipients. Established in 2004, Xeno Transplants Corporation maintains its headquarters in Brookline, Massachusetts.

Key people

Chairman of the Board · since 2007
Wayne Smith
Chief Financial Officer, Treasurer, Secretary, Director · since 2007
James Beckner
Director · since 2007
Milton Datsopoulos
Director · since 2007
Elliot Lebowitz
President, Chief Executive Officer, Director · since 2007
David Sachs
Director · since 2007
URL
IPO date
Aug 01, 2006
Employees
Domiciled in
CA
Incorporated in
US

Valuation

No data to show